Latest News
Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals, Inc. Estimates – TSX:EPRX
- Eupraxia Pharmaceuticals, Inc. (TSX:EPRX): Why Investors Are Reassessing the Next Catalyst for Canadian Market Watchers
- Eupraxia Pharmaceuticals: Promising Science, But Competition And Valuation Limit Upside
- Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
- Could Eupraxia Pharmaceuticals Inc. Become a TSX Market Watchlist Story? What Investors Need to Know (TSX:EPRX)
- Oppenheimer reiterates Eupraxia stock rating on EoE data By Investing.com
- Eupraxia Pharmaceuticals, Inc. (TSX:EPRX) Surges 5.13% as Buying Momentum Builds a Constructive Outlook
- Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology and United European Gastroenterology Medical Conferences
- Eupraxia Pharmaceuticals (TSX:EPRX) Rebounds 6.49% as Investors Reassess 52-Week EoE Data for EP-104GI
- Eupraxia Pharmaceuticals Faces Bearish Momentum as Clinical Uncertainty Raises Downside Risk — Healthcare
- Eupraxia Pharmaceuticals (TSX:EPRX) Stock Drops 13.86% After 52-Week RESOLVE Data as Phase 2b Readout Moves to December
- Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Durable EoE Data Strengthens Investor Optimism
Headlines from the last 30 days, linking to the original publishers. See all market news →